Citicoline as Neuroprotector in Preterm
- Registration Number
- NCT03966170
- Lead Sponsor
- Sherief Abd-Elsalam
- Brief Summary
Citicoline as neuroprotector in preterm
- Detailed Description
Efficacy of Citicoline as neuroprotector in preterm; A randomized controlled trial.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- Preterm on CPAP or ventilator
Exclusion Criteria
- Multiple congenital anomalies
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Citicoline Citicoline Citicoline as neuroprotector Placebo drug Placebo oral tablet Placebo
- Primary Outcome Measures
Name Time Method Number of children with affection of the brain 6 months Number of children with affection of the brain
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie citicoline's neuroprotective effects in preterm infants?
How does citicoline compare to standard-of-care neuroprotectants in preterm populations?
Are there specific biomarkers that predict citicoline response in preterm infants with brain injury?
What adverse events are associated with citicoline administration in preterm neonates and how are they managed?
What combination therapies or alternative compounds show promise as neuroprotectors for preterm brain development?
Trial Locations
- Locations (1)
Sherief Abd-Elsalam
🇪🇬Tanta, Egypt
Sherief Abd-Elsalam🇪🇬Tanta, EgyptSherief Abd-ElsalamContact